MINNEAPOLIS, MN / ACCESSWIRE / May 2, 2016 / PetVivo Holdings, Inc. (OTCPINK: PETV) an emerging biomedical device company
focused on the commercialization of innovative medical devices and therapeutics for pets is pleased to announce that the company
will be presenting at 3rd annual Growth Capital Expo MicroCap Investor Conference, held on May 3rd – 5th, 2016 at Caesars Palace in
Las Vegas, NV.
Mr. John Lai, Chief Executive Officer of PetVivo Holdings, will provide an overview of the Company's business and will be
available to participate in one-on-one meetings with investors who are registered to attend the conference.
Event: Growth Capital ExpoF Date: Wednesday, May 4, 2016 Time: 5:00 pm (Pacific Time) Location: Caesars Palace Resort in Las
Vegas
The Growth Capital Expo is the premier conference for emerging growth company finance. If you would like to attend the PetVivo
Holdings presentation in Las Vegas, registration is still open at: http://www.growthcapitalexpo.com
For more information about PetVivo Holdings, please visit our website: www.petvivo.com PetVivo's Corporate Presentation can be
found here: http://petvivo.com/wp-content/uploads/2016/04/PetVivo-Corp-Deck-04-01-16.pdf
The Growth Capital Expo brings together the best ideas, the most promising companies and the top deal makers in emerging growth
finance for three days of education and networking. The Expo features 500 of the top growth company executives, investors and
finance specialists focused on the pre-IPO and public microcap market.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of
innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device
industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the
accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently
regulated pharmaceuticals.
PetVivo's strategy is to acquire or in-license proprietary products from human medical device companies specifically for the
companion animal market. The company's product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty
patents protects the company's products, production processes and biomaterials. PetVivo's lead product, a veterinarian-administered
joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.
For more information, visit: www.PetVivo.com
Forward-Looking Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties
and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue
reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after
the date of these forward-looking statements.
CONTACT:
John Lai Chief Executive Officer PetVivo Holdings, Inc. Email: info@petvivo.com Phone: 612-296-7305
SOURCE: PetVivo Holdings, Inc.
